The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease (Q57912352)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Kremenchutzky M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Rice GP

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Baskerville J

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Wingerchuk DM

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

9 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

Pt 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

584-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Axonal damage in acute multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Clinical factors associated with increased disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Behçet's disease and the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

The clinical course of neuromyelitis optica (Devic's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWH721

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWH721

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16401620%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference